Literature DB >> 32736899

Hyperbaric oxygen for radiation-induced cystitis: A long-term follow-up.

D Pereira1, C Ferreira2, R Catarino2, T Correia2, A Cardoso2, F Reis2, M Cerqueira2, R Prisco2, O Camacho3.   

Abstract

INTRODUCTION AND
OBJECTIVES: Bladder complications may be seen in up to 12% of patients treated with pelvic irradiation. Hyperbaric oxygen therapy (HBOT) is an option for the management of radiation-induced hemorrhagic cystitis (RIHC). The aim of this study was to evaluate the efficacy of HBOT in radiation cystitis and to identify the predictive factors for a successful outcome.
MATERIAL AND METHODS: We retrospectively reviewed 105 patients diagnosed with RIHC which were treated with HBOT between 2007 and 2016 in our institution. Patients received 100% oxygen in a multiplace hyperbaric chamber at 2.4atm for 80minutes. All patients fulfilled a questionnaire documenting symptom severity pre-HBOT and at the end of the follow-up period.
RESULTS: After a median of 40 HBOT sessions, there was success rate of 92,4% in the control of hematuria. During our follow-up period (median of 63 months) 24,7% patients presented with recurrence of hematuria. The mean score of the questionnaire-assessed variables: dysuria, urinary frequency and hematuria, was significantly lower after the follow-up period (P<.05). Our data shows that the sooner HBOT is delivered after the first episode of hematuria, better response rates are achieved and lower recurrences concerning hematuria were registered (P<.05). No serious complications were observed.
CONCLUSIONS: Our results support the safety and long-term benefits of HBOT on RIHC and other distressful bladder symptoms, which represents an expected improvement of quality of life in our patients.
Copyright © 2020 AEU. Publicado por Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Cistitis inducida por radioterapia; Hematuria; Hyperbaric oxygen therapy; Lesiones por radioterapia; Radiation injuries; Radiation-induced cystitis; Terapia de oxígeno hiperbárico

Mesh:

Year:  2020        PMID: 32736899     DOI: 10.1016/j.acuro.2020.03.010

Source DB:  PubMed          Journal:  Actas Urol Esp (Engl Ed)        ISSN: 2173-5786


  2 in total

1.  A new PLA-Tween composited drug-carrying C60-Fe3O4 multifunctional ultrasound contrast agent based on three kinds of lesions.

Authors:  Baoqing Gao; Yao Feng; Xinmeng Chen; Jie Zhang
Journal:  RSC Adv       Date:  2021-09-20       Impact factor: 4.036

Review 2.  Chronic Inflammation and Radiation-Induced Cystitis: Molecular Background and Therapeutic Perspectives.

Authors:  Carole Helissey; Sophie Cavallero; Clément Brossard; Marie Dusaud; Cyrus Chargari; Sabine François
Journal:  Cells       Date:  2020-12-24       Impact factor: 6.600

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.